PharmaIN Corp. Their main focus is developing cutting-edge peptide-based therapeutics to address critical unmet medical needs. Currently, PharmaIN is advancing two innovative drug candidates.

The first candidate, PHIN-214, aims to treat refractory ascites due to advanced liver cirrhosis. It is currently undergoing a Phase 1b clinical trial in compensated or decompensated cirrhotic patients at multiple trial centers in the US. The second candidate, PHIN-1314, targets immuno-oncology treatment for solid tumors.

PharmaIN aims to initiate GLP tox in 2023, signaling a significant step forward in its development. PharmaIN boasts a highly accomplished management team. Led by founder, President, and CEO, Elijah Bolotin, who has over 20 years of experience in biopharma science and business.

The team also includes Dr. Gerardo Castillo, VP of Technology and IP, Dr. Joshua Alfaro, Director of CMC and Bioanalytical, and Cyndy Jones, Manager of Clinical Operations and Quality Assurance, among other notable professionals.

Furthermore, PharmaIN has established strategic and investment partnerships with three renowned global pharmaceutical companies, including Asahi Kasei Corporation, Shionogi & Co. Ltd, and PeptiDream Inc. With their commitment to innovation and partnerships, PharmaIN is dedicated to revolutionizing the field of biopharmaceuticals and meeting the urgent medical needs of patients worldwide